Evaluation of novel PET ligands (+)N-[11C]methyl-3-piperidyl benzilate ([11C](+)3-MPB) and its stereoisomer [11C](-)3-MPB for muscarinic cholinergic receptors in the conscious monkey brain: A PET study in comparison with [11C]4-MPB
- 1 December 2000
- Vol. 39 (2) , 182-192
- https://doi.org/10.1002/1098-2396(200102)39:2<182::aid-syn10>3.0.co;2-q
Abstract
The novel muscarinic cholinergic ligands (+)N‐[11C]methyl‐3‐piperidyl benzilate ([11C](+)3‐MPB) and its stereoisomer [11C](‐)3‐MPB were evaluated in comparison with [11C]4‐MPB in the brains of conscious monkeys (Macaca mulatta) using high‐resolution positron emission tomography (PET). The regional distribution patterns of [11C](+)3‐MPB and [11C]4‐MPB at 60–91 min postinjection were almost identical: highest in the striatum and occipital cortex; intermediate in the temporal and frontal cortices, cingulate gyrus, hippocampus, and thalamus; lower in the pons; and lowest in the cerebellum. The uptake of [11C](+)3‐MPB in all regions was higher and the dynamic range of regional uptake differences of [11C](+)3‐MPB was better than those of [11C]4‐MPB. The levels of [11C](‐)3‐MPB were much lower in all regions of the brain than [11C](+)3‐MPB and [11C]4‐MPB. Administration of scopolamine, a muscarinic cholinergic antagonist, at a dose of 50 μg/kg reduced the radioactivity of [11C](+)3‐MPB and [11C]4‐MPB in all regions except the cerebellum. Time–activity curves of [11C](+)3‐MPB peaked in all regions, while those of [11C]4‐MPB showed gradual increases with time in all regions except the thalamus, pons, and cerebellum. Two graphical analyses (Logan plot and Patlak plot) with plasma radioactivity as an input function into the brain were applied to evaluate receptor binding in vivo. [11C](+)3‐MPB showed linear regression curves on Logan plot analysis and nonlinear curves on Patlak plot in all regions, suggesting that [11C](+)3‐MPB bound reversibly to the muscarinic receptors. The in vivo binding parameters as well as uptake at 60–91 min postinjection of [11C](+)3‐MPB were consistent with muscarinic receptor density in the brain as reported in vitro. Synapse 39:182–192, 2001.Keywords
This publication has 36 references indexed in Scilit:
- Kinetic Evaluation of Positron-Emitting Muscarinic Receptor Ligands Employing Direct Intracarotid InjectionJournal of Cerebral Blood Flow & Metabolism, 1996
- In vivo Muscarinic Cholingeric Receptor Imaging in Human Brain with [11C]Scopolamine and Positron Emission TomographyJournal of Cerebral Blood Flow & Metabolism, 1992
- Age‐related decreases in muscarinic cholinergic receptor binding in the human brain measured with positron emission tomography (PET)Journal of Neuroscience Research, 1990
- Mapping muscarinic receptors in human and baboon brain using [N‐11C‐methyl]‐benztropineSynapse, 1990
- Synthesis of radiotracers for studying muscarinic cholinergic receptors in the living human brain using positron emission tomography: [11C]dexetimide and [11C]levetimideInternational Journal of Radiation Applications and Instrumentation. Part A. Applied Radiation and Isotopes, 1988
- Autoradiographic Study of Regional Protein Synthesis in Focal Cerebral Ischemia with TCA Wash and Image Subtraction TechniquesJournal of Cerebral Blood Flow & Metabolism, 1987
- Neuroreceptor Assay with Positron Emission Tomography: Equilibrium versus Dynamic ApproachesJournal of Cerebral Blood Flow & Metabolism, 1986
- Cholinergic function and intellectual decline in Alzheimer's diseaseNeuroscience, 1986
- High dosage anticholinergic therapy in dystoniaNeurology, 1983
- Alterations of brain neurotransmitter receptor binding in Huntington's choreaBrain Research, 1976